ASMB
Assembly Biosciences Inc
25.00$
-1.5%
vs. previous close
Closing price · As of: Sep 18, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 41.0% | 51.1% | 54.6% | 72.7% | 83.0% | 81.3% | 79.3% | 80.7% | 95.3% | 97.8% | 96.9% | 98.8% | |
| 40.8% | 20.3% | 29.1% | 48.5% | 15.5% | 13.4% | 21.0% | 23.9% | 51.5% | 14.5% | 32.2% | 22.7% | |
| 40.8% | 50.6% | 54.0% | 70.8% | 81.4% | 78.8% | 76.4% | 76.7% | 90.0% | 95.2% | 94.1% | 96.3% | |
| – | – | – | 1.3% | 0.9% | 1.0% | 0.4% | 0.2% | 0.9% | 0.0% | 0.3% | 0.4% | |
| 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | -2.3% | – | – | |
| 0.2% | 0.1% | 0.2% | 0.5% | 0.2% | 0.5% | 0.6% | 3.8% | 0.7% | – | – | – | |
| 17.9% | 9.4% | 12.9% | 7.5% | 4.7% | 3.6% | 4.5% | 0.0% | – | – | – | – | |
| 40.7% | 21.7% | 29.6% | 17.1% | 10.8% | 8.3% | 10.2% | – | – | – | – | – | |
| 17.8% | 11.2% | 18.6% | 33.2% | 21.4% | 21.5% | 15.1% | 11.6% | 18.8% | 70.0% | 72.0% | 19.7% | |
| 1.5% | 2.5% | 7.3% | 8.0% | 6.9% | 7.0% | 8.6% | 8.4% | 16.0% | 28.7% | 40.1% | 18.9% | |
| – | – | – | – | – | 0.9% | 1.2% | 1.6% | 3.3% | 0.9% | 0.4% | 0.2% | |
| 1.3% | 1.0% | 2.4% | 1.3% | 1.4% | 0.5% | 1.6% | 1.4% | 2.4% | 0.3% | 0.5% | 0.5% | |
| 0.0% | 0.0% | 0.0% | 0.0% | – | – | – | – | – | – | – | – | |
| 82.2% | 88.8% | 81.4% | 66.8% | 78.6% | 78.5% | 84.9% | 88.4% | 81.2% | 30.0% | 28.0% | 80.3% | |
| -190.3% | -122.6% | -212.2% | -148.3% | -127.5% | -126.3% | -177.1% | -330.5% | -711.8% | -574.3% | -693.1% | -323.0% | |
| 1.0% | 1.2% | 1.8% | 1.0% | 0.9% | 1.0% | 1.4% | 1.9% | 4.0% | 3.3% | 5.0% | 4.4% |
Data as of: September 18, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.